These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24491240)

  • 1. Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black.
    Robles NR; Macias JF; Herrera J
    Eur J Intern Med; 2014 Feb; 25(2):193-6. PubMed ID: 24491240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of iron deficiency and anemia in cardio-renal syndromes.
    Attanasio P; Ronco C; Anker SD; Cicoira M; von Haehling S
    Semin Nephrol; 2012 Jan; 32(1):57-62. PubMed ID: 22365163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents.
    Geisler BP
    Expert Opin Biol Ther; 2010 Aug; 10(8):1209-16. PubMed ID: 20557272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaemia in older people with chronic heart failure: The potential cost.
    Man-Fai Sim V; Nam MC; Riley S; Yousef Z; Hurley J; Cheung WY; O'Mahony S
    Technol Health Care; 2009; 17(5-6):377-85. PubMed ID: 20051617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythropoiesis-stimulating agents in congestive heart failure patients].
    Robles Perez-Monteoliva NR; Macías Núñez JF; Herrera Pérez de Villar J
    Med Clin (Barc); 2014 Mar; 142(5):215-8. PubMed ID: 24012446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correcting anemia in heart failure: the efficacy and safety of erythropoiesis-stimulating agents.
    Lawler PR; Filion KB; Eisenberg MJ
    J Card Fail; 2010 Aug; 16(8):649-58. PubMed ID: 20670844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of erythropoiesis-stimulating agents in the treatment of anemia.
    Fishbane S
    Am J Manag Care; 2010 Mar; 16 Suppl Issues():S67-73. PubMed ID: 20297874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future directions in management of anemia in heart failure.
    Agarwal AK; Katz SD
    Heart Fail Clin; 2010 Jul; 6(3):385-95. PubMed ID: 20630412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaemia management in cardio renal disease.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    J Ren Care; 2010 May; 36 Suppl 1():86-96. PubMed ID: 20586904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome.
    Iaina A; Silverberg DS; Wexler D
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):95-100. PubMed ID: 16265380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents and heart failure.
    Lipšic E; van der Meer P; van Veldhuisen DJ
    Cardiovasc Ther; 2011 Aug; 29(4):e52-9. PubMed ID: 20973926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction between heart failure and other heart diseases, renal failure, and anemia.
    Silverberg DS; Wexler D; Iaina A; Schwartz D
    Semin Nephrol; 2006 Jul; 26(4):296-306. PubMed ID: 16949468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cardio-renal anemia syndrome.
    Iaina A; Silverberg DS; Wexler D; Iaina Nomy L
    Med Pregl; 2007; 60 Suppl 2():145-50. PubMed ID: 18928182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardio-renal syndrome and anaemia].
    Jakić M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():38-45. PubMed ID: 20232550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoiesis-stimulating agents in kidney and cardiac disease.
    Fluck R
    Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of erythropoiesis stimulating therapy for anemia in chronic heart failure: A meta-analysis of randomized clinical trials.
    Kang J; Park J; Lee JM; Park JJ; Choi DJ
    Int J Cardiol; 2016 Sep; 218():12-22. PubMed ID: 27209352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.
    van Veldhuisen DJ; Anker SD; Ponikowski P; Macdougall IC
    Nat Rev Cardiol; 2011 May; 8(9):485-93. PubMed ID: 21629210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization.
    Silverberg DS; Wexler D; Blum M; Tchebiner J; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Zubkov A; Steinbruch S; Iaina A
    Clin Nephrol; 2002 Jul; 58 Suppl 1():S37-45. PubMed ID: 12227725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.